These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
198 related items for PubMed ID: 7731498
1. Modulation of growth hormone-releasing activity of hexarelin in man. Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E. Neuroendocrinology; 1995 Jan; 61(1):51-6. PubMed ID: 7731498 [Abstract] [Full Text] [Related]
2. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. Maccario M, Arvat E, Procopio M, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E. Metabolism; 1995 Jan; 44(1):134-8. PubMed ID: 7854159 [Abstract] [Full Text] [Related]
3. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man. Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E. Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449 [Abstract] [Full Text] [Related]
4. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E. J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341 [Abstract] [Full Text] [Related]
5. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose. Maccario M, Procopio M, Grottoli S, Oleandri SE, Razzore P, Camanni F, Ghigo E. J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634 [Abstract] [Full Text] [Related]
6. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine. Rigamonti AE, Marazzi N, Cella SG, Cattaneo L, Müller EE. J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881 [Abstract] [Full Text] [Related]
7. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F. J Clin Endocrinol Metab; 1994 Mar; 78(3):693-8. PubMed ID: 8126144 [Abstract] [Full Text] [Related]
8. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man. Arvat E, Di Vito L, Gianotti L, Ramunni J, Boghen MF, Deghenghi R, Camanni F, Ghigo E. Metabolism; 1997 Jan; 46(1):83-8. PubMed ID: 9005975 [Abstract] [Full Text] [Related]
9. Interaction of the growth hormone releasing peptide hexarelin with somatostatin. Massoud AF, Hindmarsh PC, Brook CG. Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393 [Abstract] [Full Text] [Related]
10. Radiation and neuroregulatory control of growth hormone secretion. Ogilvy-Stuart AL, Wallace WH, Shalet SM. Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820 [Abstract] [Full Text] [Related]
11. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man. Arvat E, Maccagno B, Ramunni J, Gianotti L, Di Vito L, Deghenghi R, Camanni F, Ghigo E. J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817 [Abstract] [Full Text] [Related]
12. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children. Guzzaloni G, Grugni G, Morabito F. Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807 [Abstract] [Full Text] [Related]
13. Influence of endogenous cholinergic tone and alpha-adrenergic pathways on growth hormone responses to His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the dog. Muruais J, Peñalva A, Dieguez C, Casanueva FF. J Endocrinol; 1993 Aug; 138(2):211-8. PubMed ID: 8228729 [Abstract] [Full Text] [Related]
14. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. J Clin Endocrinol Metab; 1995 Mar; 80(3):942-7. PubMed ID: 7883854 [Abstract] [Full Text] [Related]
15. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration. Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi M, Boffano GM, Mucci M, Boghen MF, Camanni F. J Endocrinol Invest; 1994 Mar; 17(3):157-62. PubMed ID: 8051337 [Abstract] [Full Text] [Related]
16. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity. Massoud AF, Hindmarsh PC, Matthews DR, Brook CG. Clin Endocrinol (Oxf); 1996 May; 44(5):555-62. PubMed ID: 8762732 [Abstract] [Full Text] [Related]
17. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients. Grottoli S, Razzore P, Arvat E, Oleandri SE, Rossetto R, Ciccarelli E, Camanni F, Ghigo E. J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917 [Abstract] [Full Text] [Related]
18. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E. J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504 [Abstract] [Full Text] [Related]